Evidence map›Paper›PMID 33645864›Full record

Trial reportNeurourology and urodynamics2021

A prospective, multicenter, international study to explore the effect of three different amplitude settings in female subjects with urinary urge incontinence receiving interstim therapy.

Dean Elterman, Michael Ehlert, Dirk De Ridder, Rebecca McCrery, Mahreen Pakzad, Melissa R Kaufman, Sagar Shah, Eric Margolis, Raviender Bukkapatnam, Gayle Johnson and 4 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Neurourology and urodynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 4 countries.

Dean EltermanUniversity of Toronto, Toronto, Ontario, Canada.
Michael EhlertMinnesota Urology, Fridley, Minnesota, USA.
Dirk De RidderUZ Leuven, Leuven, Belgium.ORCID 0000-0001-6914-0077
Rebecca McCreryAdult Pediatric Urology and Urogynecology, Omaha, Nebraska, USA.
Mahreen PakzadUniversity College London, London, UK.
Melissa R KaufmanVanderbilt University Medical Center, Nashville, Tennessee, USA.
Sagar ShahEast Coast Institute for Research, Jacksonville, Florida, USA.
Eric MargolisUrologic Research and Consulting LLC, Englewood, New Jersey, USA.
Raviender BukkapatnamFlorida Urology Partners, Tampa, Florida, USA.
Gayle JohnsonMedtronic, Minneapolis, Minnesota, USA.
Lance ZirpelMedtronic, Minneapolis, Minnesota, USA.
Kira StolenMedtronic, Minneapolis, Minnesota, USA.
Mylène ChampsMedtronic, Minneapolis, Minnesota, USA.
Colin GoudelockeOchsner Medical Center, Los Angeles, USA.
Medtronic (United States) · USAdult and Pediatric Dermatology · USAdventHealth Tampa · USDwight Englewood School · USMinnesota Oncology · USOchsner Medical Center · USUniversitair Ziekenhuis Leuven · BEUniversity College London · GBUniversity of Toronto · CAVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of this study is to evaluate the effect of sub-sensory amplitude settings of sacral neuromodulation therapy on overactive bladder symptoms in subjects with urinary urge incontinence.

methodsSubjects who qualified for a neurostimulator device implant were randomized to one of three amplitude settings (50% of sensory threshold [ST], 80% of ST, and ST). Subjects completed urinary voiding diaries (3-day), International consultation on incontinence modular questionnaire-overactive bladder symptoms quality of life questionnaire, and patient global impression of improvement (PGI-I) to assess change in voiding symptoms and quality of life (QoL) from baseline through 12 weeks.

resultsForty-eight subjects had a successful test stimulation, 46 were implanted with a neurostimulator device and 43 completed the 12-week follow-up visit. The change from baseline to 12 weeks is -3.0 urinary incontinence (UI) episodes/day (95% confidence interval [CI]: -4.4 to -1.7) for the 50% of sensory threshold group, -2.9 UI episodes/day (95% CI: -4.7 to -1.2) for 80% of sensory threshold group, and -3.6 UI episodes/day (95% CI: -5.2 to -1.9) for the sensory threshold group. In each randomized group, improvements were observed in health-related QoL, its subscales, and symptom interference. Subjects across all three randomization groups reported on the PGI-I that their bladder condition was better at 12 weeks compared to before they were treated with InterStim therapy.

conclusionThese findings provide insights into possible advancements in the postimplantation phase of therapy with potential for improved patient comfort and increased device longevity.

Indexed as

Electric Stimulation TherapyFemaleHumansMiddle AgedProspective StudiesUrinary Incontinence, Urgeoveractive bladderquality of lifesacral neuromodulationsensory thresholdsurinary incontinence

Identifiers

PMID33645864
PMCPMC8248091
OpenAlexW3134528631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.